Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.
about
Kampo medicines for gastrointestinal tract disorders: a review of basic science and clinical evidence and their future applicationChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging TreatmentsClinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancerAdvances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer.Japanese herbal medicine in functional gastrointestinal disorders.Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients.A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab.The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)Traditional Japanese Kampo Medicine: Clinical Research between Modernity and Traditional Medicine-The State of Research and Methodological Suggestions for the FutureHerbal medicines for the treatment of cancer chemotherapy-induced side effects.Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumorsDouble-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.Use of chinese herb medicine in cancer patients: a survey in southwestern china.Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic reviewFirst nationwide attitude survey of Japanese physicians on the use of traditional Japanese medicine (kampo) in cancer treatment.Ginseng in traditional herbal prescriptions.Significance of Kampo, traditional Japanese medicine, in supportive care of cancer patientsRole of Kampo medicine in integrative cancer therapy.Decreased absorption of midazolam in the stomach due to low pH induced by co-administration of Banha-sasim-tang.Kampo medicine for palliative care in Japan.Preventive Effects of a Chinese Herbal Formula, Shengjiang Xiexin Decoction, on Irinotecan-Induced Delayed-Onset Diarrhea in Rats.Simultaneous determination of 14 active constituents of Shengjiang Xiexin decoction using ultrafast liquid chromatography coupled with electrospray ionization tandem mass spectrometry.Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis.Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.Patient-centered care in lung cancer: exploring the next milestones.Microbiota as a mediator of cancer progression and therapy.Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer.CPT-11-Induced Delayed Diarrhea Develops via Reduced Aquaporin-3 Expression in the Colon.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C).Effect of Hangeshashin-To (Japanese Herbal Medicine Tj-14) on Tolerability of Irinotecan: Propensity Score and Instrumental Variable Analyses
P2860
Q26830898-3B43D32F-AF91-457A-84B5-0086CFC4695BQ28079705-9F4E7B5E-1FCD-4D74-A5AF-4858E33D3DACQ33429673-623A8828-4E95-45C0-9600-685A3CB376FDQ33659224-B39B0839-02CD-47AC-89C9-1900DDCCABCFQ34143122-23A86286-A4A3-4FBB-9BDE-3737827D1213Q34361724-0030CF54-D62B-4D24-A9CE-B93DFB25F439Q34510194-ECF5D51A-D7E0-4303-BFD7-E91DA3E5AA87Q34996195-03432327-C255-47A1-9739-2287E423D497Q35043493-FDD4A5E0-09CD-4DC7-9B2C-AF829C844679Q35066654-708C9E7C-E753-4C0D-9289-3125101ED48CQ35667216-1BCC7BB4-65DF-4C3E-BFD9-219EA78CA798Q35799588-4C360BC5-4648-49CB-BE72-A6E90B393190Q36171894-C550F809-E832-422B-90A1-6A54C43EE534Q36246975-AC155639-22A0-42EA-9A8D-ED1C7C07881CQ36411753-AD7F5900-253B-4202-9A44-C3960AAE1452Q36477176-0FE220DD-A3C0-4CFC-8FD9-75F8F1BDBC75Q36861125-9FBEBBDC-8929-4FDC-933E-B3EA626DE193Q36990461-9B30093D-E017-4C09-8AC3-B217DAB9F924Q37044478-1EFC4018-BB33-4FD5-9649-EFE77C59351AQ37367360-6C1C1955-B438-4549-A12C-5870130F6C7FQ37513030-537665D8-7335-4B17-BB77-49BF49DA39A3Q37607371-528C213E-C39E-4A02-97A6-EE60D132B407Q37689644-F02B6AF9-3510-4A7B-AD8F-D81900670128Q37724518-74FB059B-B947-4140-B078-C2F22B2048C4Q37731433-B97CA97B-EC82-4C35-A261-4C04685B1C51Q38656497-5570A9A8-C489-4D1A-A5DB-4CDCA018E361Q38935534-77783180-33A0-4937-980B-F5FF5872DFF1Q42180635-F97374E8-6179-427B-B33E-150AA02E32F6Q47102325-80F58D60-4E98-40AE-B29E-AB004CC82012Q47724378-C2C5806A-6459-41FE-8879-1AAFFD47206FQ52362144-74906490-0B5B-442D-A0F5-1A9281002A93Q55311059-923BA5C6-9B4F-46A8-A3BD-8AFDA4DAE058Q58697371-6AA8C3EB-E9DC-4FE8-9B68-FED923F7CABC
P2860
Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Preventive effect of Kampo med ...... ed non-small-cell lung cancer.
@en
Preventive effect of Kampo medicine
@nl
type
label
Preventive effect of Kampo med ...... ed non-small-cell lung cancer.
@en
Preventive effect of Kampo medicine
@nl
prefLabel
Preventive effect of Kampo med ...... ed non-small-cell lung cancer.
@en
Preventive effect of Kampo medicine
@nl
P2093
P1476
Preventive effect of Kampo med ...... ed non-small-cell lung cancer.
@en
P2093
Keigo Tominaga
Kiyoshi Mori
Tetsuro Kondo
Yasuhiko Kano
Yukari Kamiyama
P2888
P304
P356
10.1007/S00280-003-0585-0
P577
2003-04-09T00:00:00Z